Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers

Ottervald, Jan ; Franzen, Bo ; Nilsson, Kerstin ; Andersson, Lars I. ; Khademi, Mohsen ; Eriksson, Bodil ; Kjellstrom, Sven ; Marko-Varga, György LU ; Végvári, Ákos LU and Harris, Robert A. , et al. (2010) In Journal of Proteomics 73(6). p.1117-1132
Abstract
Multiple sclerosis (MS) is a neuro-inflammatory and neurodegenerative disease that results in damage to myelin sheaths and axons in the central nervous system and which preferentially affects young adults. We performed a proteomics-based biomarker discovery study in which cerebrospinal fluid (CSF) from MS and control individuals was analyzed (n=112). Ten candidate biomarkers were selected for evaluation by quantitative immunoassay using an independent cohort of MS and control subjects (n=209). In relapsing remitting MS (ARMS) patients there were significant increases in the CSF levels of alpha-1 antichymotrypsin (A1AC), alpha-1 macroglobulin (A2MG) and fibulin 1 as compared to control subjects. In secondary progressive MS (SPMS) four... (More)
Multiple sclerosis (MS) is a neuro-inflammatory and neurodegenerative disease that results in damage to myelin sheaths and axons in the central nervous system and which preferentially affects young adults. We performed a proteomics-based biomarker discovery study in which cerebrospinal fluid (CSF) from MS and control individuals was analyzed (n=112). Ten candidate biomarkers were selected for evaluation by quantitative immunoassay using an independent cohort of MS and control subjects (n=209). In relapsing remitting MS (ARMS) patients there were significant increases in the CSF levels of alpha-1 antichymotrypsin (A1AC), alpha-1 macroglobulin (A2MG) and fibulin 1 as compared to control subjects. In secondary progressive MS (SPMS) four additional proteins (contactin 1, fetuin A, vitamin D binding protein and angiotensinogen (ANGT)) were increased as compared to control subjects. In particular, ANGT was increased 3-fold in SPMS, indicating a potential as biomarker of disease progression in MS. In PPMS, A1AC and A2MG exhibit significantly higher CSF levels than controls, with a trend of increase for ANGT. Classification models based on the biomarker panel could identify 70% of the RRMS and 80% of the SPMS patients correctly. Further evaluation was conducted in a pilot study of CSF from RRMS patients (n=36), before and after treatment with natalizumab. (C) 2010 Elsevier B.V. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Treatment, Prognosis, Biomarkers, Proteomics, Multiple sclerosis, CSF
in
Journal of Proteomics
volume
73
issue
6
pages
1117 - 1132
publisher
Elsevier
external identifiers
  • wos:000277763800009
  • scopus:77950597049
  • pmid:20093204
ISSN
1874-3919
DOI
10.1016/j.jprot.2010.01.004
language
English
LU publication?
yes
id
481d1f1d-f0cc-4ba7-90d7-caac88204ef9 (old id 1617444)
date added to LUP
2016-04-01 10:58:11
date last changed
2022-05-18 03:36:23
@article{481d1f1d-f0cc-4ba7-90d7-caac88204ef9,
  abstract     = {{Multiple sclerosis (MS) is a neuro-inflammatory and neurodegenerative disease that results in damage to myelin sheaths and axons in the central nervous system and which preferentially affects young adults. We performed a proteomics-based biomarker discovery study in which cerebrospinal fluid (CSF) from MS and control individuals was analyzed (n=112). Ten candidate biomarkers were selected for evaluation by quantitative immunoassay using an independent cohort of MS and control subjects (n=209). In relapsing remitting MS (ARMS) patients there were significant increases in the CSF levels of alpha-1 antichymotrypsin (A1AC), alpha-1 macroglobulin (A2MG) and fibulin 1 as compared to control subjects. In secondary progressive MS (SPMS) four additional proteins (contactin 1, fetuin A, vitamin D binding protein and angiotensinogen (ANGT)) were increased as compared to control subjects. In particular, ANGT was increased 3-fold in SPMS, indicating a potential as biomarker of disease progression in MS. In PPMS, A1AC and A2MG exhibit significantly higher CSF levels than controls, with a trend of increase for ANGT. Classification models based on the biomarker panel could identify 70% of the RRMS and 80% of the SPMS patients correctly. Further evaluation was conducted in a pilot study of CSF from RRMS patients (n=36), before and after treatment with natalizumab. (C) 2010 Elsevier B.V. All rights reserved.}},
  author       = {{Ottervald, Jan and Franzen, Bo and Nilsson, Kerstin and Andersson, Lars I. and Khademi, Mohsen and Eriksson, Bodil and Kjellstrom, Sven and Marko-Varga, György and Végvári, Ákos and Harris, Robert A. and Laurell, Thomas and Miliotis, Tasso and Matusevicius, Darius and Salter, Hugh and Ferm, Mats and Olsson, Tomas}},
  issn         = {{1874-3919}},
  keywords     = {{Treatment; Prognosis; Biomarkers; Proteomics; Multiple sclerosis; CSF}},
  language     = {{eng}},
  number       = {{6}},
  pages        = {{1117--1132}},
  publisher    = {{Elsevier}},
  series       = {{Journal of Proteomics}},
  title        = {{Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers}},
  url          = {{http://dx.doi.org/10.1016/j.jprot.2010.01.004}},
  doi          = {{10.1016/j.jprot.2010.01.004}},
  volume       = {{73}},
  year         = {{2010}},
}